1S90 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Seres Therapeutics Inc

Watchlist Manager

Watchlist

Price: 4.18 EUR 0.24% Market Closed

Market Cap: €37.8m

	Seres Therapeutics Inc F:1S90	US
N	Nektar Therapeutics F:ITH	US
	BAVARIA Industries Group AG XETRA:B8A	DE
	Total Helium Ltd OTC:TTLHD	CA

Profitability Summary

Seres Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-4 154%

Negative 3Y Average Operating Margin

-8 880%

Declining Operating Margin

-63% > -4 154%

Negative Net Margin

-1 193%

Negative 3Y Average Net Margin

-533%

Declining Net Margin

-119% > -1 193%

Negative Free Cash Flow Margin

-2 724%

Negative 3Y Average Free Cash Flow Margin

-2 189%

Declining Free Cash Flow Margin

-103% > -2 724%

Negative ROE

-67%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-79%

Declining ROIC

-72% > -86%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.